Commerce Bank Cuts Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Commerce Bank reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 26.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 10,701 shares of the biopharmaceutical company’s stock after selling 3,920 shares during the quarter. Commerce Bank’s holdings in Halozyme Therapeutics were worth $613,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Segall Bryant & Hamill LLC raised its holdings in shares of Halozyme Therapeutics by 16.3% in the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock valued at $20,330,000 after purchasing an additional 49,856 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Halozyme Therapeutics in the 3rd quarter valued at about $1,899,000. Quest Partners LLC lifted its position in shares of Halozyme Therapeutics by 1,386.0% during the 3rd quarter. Quest Partners LLC now owns 9,793 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 9,134 shares in the last quarter. TrinityPoint Wealth LLC purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $214,000. Finally, South Street Advisors LLC bought a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $9,812,000. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Trading Down 2.5 %

Shares of HALO stock opened at $47.79 on Tuesday. The stock has a market capitalization of $6.08 billion, a price-to-earnings ratio of 16.14, a PEG ratio of 0.45 and a beta of 1.29. The company’s fifty day simple moving average is $54.58 and its two-hundred day simple moving average is $53.65. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15.

Insider Activity

In related news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total transaction of $590,900.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $39,988,802.96. The trade was a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders sold 60,000 shares of company stock worth $3,425,000. 2.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of recent analyst reports. Benchmark restated a “buy” rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. HC Wainwright restated a “buy” rating and set a $68.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $58.00 to $62.00 in a report on Monday, October 7th. Morgan Stanley boosted their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.